Abstract

The purpose of this program project grant is to investigate the biology and improve transplantation in clinical malignancy, syngeneic, and autologous marrow transplantation in clinical malignancy, diseases of marrow failure and in certain genetic diseases. The proposal is made up of five projects: 1. Preparative Regimens and Anti- Tumor Trials. This project is designed to investigate new preparative regimens in various hematological malignancies and methods of """"""""purging"""""""" marrow for autologous transplantation in acute lymphocytic leukemia. 2.Graft-versus-Host Reaction and Disease.
The aims of this project are to investigate the basic mechanisms involved and therapeutic prevention and treatment of Graft-versus-Host Disease. 4. Pharmacology in Bone Marrow Transplantation. The purpose of this project is to provide knowledge as to the pharmacokinetics and mechanism of agents employed in preparative regimens, in vitro purging of tumor cells, and agents used to prevent and treat graft-versus-host disease. 5. Biology and viral and other Infections in Bone Marrow Transplantation. the purpose of this project is to better define the biologic mechanisms and develop strategies for the preventional and therapy of viral and other infections. 6. Core components. This project represents the core of the program and includes administrative and support services, cytogenetics and RFLP analysis, statistics and data, stem cell laboratory, pathology and outpatient services.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA015396-18
Application #
3092665
Study Section
Special Emphasis Panel (SRC (H1))
Project Start
1976-09-30
Project End
1993-11-30
Budget Start
1990-12-10
Budget End
1991-11-30
Support Year
18
Fiscal Year
1991
Total Cost
Indirect Cost

  Institution

Name
Johns Hopkins University
Department
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218

  Publications

Schoch, Laura K; Cooke, Kenneth R; Wagner-Johnston, Nina D et al. (2018) Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv 2:2226-2229
Kasamon, Yvette L; Fuchs, Ephraim J; Zahurak, Marianna et al. (2018) Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. Biol Blood Marrow Transplant 24:1022-1028
Robinson, Tara M; Prince, Gabrielle T; Thoburn, Chris et al. (2018) Pilot trial of K562/GM-CSF whole-cell vaccination in MDS patients. Leuk Lymphoma 59:2801-2811
Grant, Melanie L; Bollard, Catherine M (2018) Cell therapies for hematological malignancies: don't forget non-gene-modified t cells! Blood Rev 32:203-224
Ghosh, Nilanjan; Ye, Xiaobu; Tsai, Hua-Ling et al. (2017) Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma. Biol Blood Marrow Transplant 23:1903-1909
Majzner, Robbie G; Mogri, Huzefa; Varadhan, Ravi et al. (2017) Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy. Biol Blood Marrow Transplant 23:612-617
Alonso, Salvador; Jones, Richard J; Ghiaur, Gabriel (2017) Retinoic acid, CYP26, and drug resistance in the stem cell niche. Exp Hematol 54:17-25
Cruz, Conrad R Y; Bollard, Catherine M (2017) Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells. Curr Drug Targets 18:271-280
Fuchs, Ephraim Joseph (2017) Related haploidentical donors are a better choice than matched unrelated donors: Point. Blood Adv 1:397-400
Kanakry, Christopher G; Bolaños-Meade, Javier; Kasamon, Yvette L et al. (2017) Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. Blood 129:1389-1393

Showing the most recent 10 out of 456 publications